Skip to main content
RegeneronRevenue

Regeneron Q3 Revenue Rises 36% to $5.12 Billion

Source: Autobound Signal API · 94 signals tracked for Regeneron · updated

Get Regeneron's live signals in Claude or ChatGPT, or by API

AskWhat changed at Regeneron this week? Use Autobound signals for regeneron.com.

What happened

Regeneron Pharmaceuticals reported third-quarter 2026 revenue of $5.116 billion, up 36% year over year.

Source

Article excerpt

Highlighted: the sentence this signal was extracted from

Regeneron Pharmaceuticals (NASDAQ:REGN) reported third-quarter 2026 revenue of $5.116 billion, up 36% year over year, while GAAP diluted earnings per share increased 35% to $18.45. Net income increased 33% to $1.949 billion, while revenue from the company's collaboration with Sanofi rose 68% to $2.724 billion compared with the same quarter last year. The company reported that its expanded alliance with Sanofi includes a $1 billion upfront payment and up to $7 billion in conditional milestone payments. U.S. EYLEA HD sales increased 62% to $699 million, although combined U.S. EYLEA HD and EYLEA sales declined 1% to $1.099 billion, while global Libtayo sales rose 51% to $550 million. The expanded Sanofi agreement includes a $1 billion upfront payment expected to be recognized as fourth-quarter collaboration revenue, alongside up to $7 billion in conditional milestones. Regeneron also received FDA approval for Pasatru for adults with fibrodysplasia ossificans progressiva and raised its 2026 research spending outlook while lowering expected selling and administrative expenses and increasing its expected product gross margin. Regeneron develops and commercializes medicines for serious diseases across oncology, immunology, cardiovascular, eye and rare disease markets, with major products including EYLEA, Dupixent through its Sanofi collaboration and Libtayo.

grafa.com/en/news/united-states/regeneron-q3-2026-revenue-rises-36-pe...Read the full source

Extracted by Autobound

From the Signal API record
Event
Revenue

What this signalsRevenue results often set the next budget cycle.

Amount named
$5.1B

The full record

From the Signal API record

Numbers

Amount named in the story
$5.1B

Details

Ticker
NASDAQ:REGN

Extraction

Confidence
95%
Detected
Oct 30, 2026
signal_type
news
signal_subtype
has_revenue

Use this data

Get every revenue signal for Regeneron and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Regeneron this week?”

  2. Send it to your own tools

    The Signal API returns revenue signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/756f5061-234f-2927-6584-757d26ba70c1 returns this record as JSON. POST /v1/companies/enrich returns every signal for regeneron.com.

{
  "signal_id": "756f5061-234f-2927-6584-757d26ba70c1",
  "signal_type": "news",
  "signal_subtype": "has_revenue",
  "detected_at": "2026-10-30T12:15:03+00:00",
  "company": {
    "name": "Regeneron",
    "domain": "regeneron.com"
  },
  "data": {
    "url": "https://grafa.com/en/news/united-states/regeneron-q3-2026-revenue-rises-36-percent",
    "title": "Regeneron Q3 Revenue Rises 36% to $5.12 Billion - grafa.com",
    "ticker": "NASDAQ:REGN",
    "excerpt": "Regeneron Pharmaceuticals (NASDAQ:REGN) reported third-quarter 2026 revenue of $5.116 billion, up 36% year over year, while GAAP diluted earnings per share increased 35% to $18.45. Net income increased 33% to $1.949 billion, while revenue from the company's collaboration with Sanofi rose 68% to $2.724 billion compared with the same quarter last year. The company reported that its expanded alliance with Sanofi includes a $1 billion upfront payment and up to $7 billion in conditional milestone payments. U.S. EYLEA HD sales increased 62% to $699 million, although combined U.S. EYLEA HD and EYLEA sales declined 1% to $1.099 billion, while global Libtayo sales rose 51% to $550 million. The expanded Sanofi agreement includes a $1 billion upfront payment expected to be recognized as fourth-quarter collaboration revenue, alongside up to $7 billion in conditional milestones. Regeneron also received FDA approval for Pasatru for adults with fibrodysplasia ossificans progressiva and raised its 2026 research spending outlook while lowering expected selling and administrative expenses and increasing its expected product gross margin. Regeneron develops and commercializes medicines for serious diseases across oncology, immunology, cardiovascular, eye and rare disease markets, with major products including EYLEA, Dupixent through its Sanofi collaboration and Libtayo.",
    "summary": "Regeneron Pharmaceuticals reported third-quarter 2026 revenue of $5.116 billion, up 36% year over year.",
    "planning": false,
    "image_url": "https://s3.ap-southeast-2.amazonaws.com/assets.hq.grafa.com/regeneron-earnings-1200x675.webp",
    "confidence": 0.95,
    "published_at": "2026-10-30T12:15:03Z",
    "article_sentence": "Regeneron Pharmaceuticals (NASDAQ:REGN) reported third-quarter 2026 revenue of $5.116 billion, up 36% year over year, while GAAP diluted earnings per share increased 35% to $18.45.",
    "amount_normalized": 5116000000
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.